141W94 and Indinavir Combination with NRTIs for HIV-1 Treatment

This study focuses on comparing the safety and antiviral effectiveness of a drug called 141W94 to another drug named indinavir. Both of these drugs are used in combination with nucleoside reverse transcriptase inhibitors (NRTIs), which are medications that help control HIV infection. The study involves individuals who have previously used NRTIs but have not used protease inhibitors, a type of HIV medication. The main goal is to find out if 141W94 can be as effective and safe as indinavir when used with NRTIs for a period of 48 weeks. This research is important as it could potentially lead to new treatment options for HIV-1-infected patients. During this study, participants will receive either 141W94 or indinavir along with their NRTIs. The effects of these drugs will be monitored over 48 weeks to evaluate their safety and effectiveness. The study also looks at how other drugs might affect the way the body processes 141W94. The results will be measured by looking at changes in HIV levels in the blood and any side effects that may occur. This will help researchers understand the potential benefits and risks of using 141W94 in combination with NRTIs.